Department of Respiratory Medicine, Chinese PLA General Hospital, Beijing, China.
Expert Rev Anti Infect Ther. 2021 Jun;19(6):769-776. doi: 10.1080/14787210.2021.1848544. Epub 2020 Dec 3.
: Gram-negative bacterial bloodstream infections (BSIs) are associated with high morbidity and mortality. The present study examines the incidence, clinical characteristics, microbiological features, drug resistance and mortality associated with Gram-negative bacterial BSIs at a tertiary-care hospital in Beijing, China.: This retrospective cohort study of patients with Gram-negative bacterial BSIs was performed between 1 January 2010 and 31 December 2018 at the Chinese Peoples Liberation Army General Hospital.: A total of 6867 episodes of Gram-negative bacterial BSIs occurred among 3199 patients over 9 years. The overall incidence of Gram-negative bacterial BSIs fluctuated from 2.30 to 2.55 episodes per 1000 admissions over 9 years. was the major pathogen (34.3%). The antibiotic resistance of ESBLs-producing was higher than non-ESBLs producing including the majority of antibiotics, but to carbapenems (0.7% VS 5.1%). Between 2010 and 2018, the overall mortality of Gram-negative bacterial BSIs decreased from 11.41% to 9.05% (X = 6.95, P = 0.434).: Cephalosporins and carbapenem antibiotics were considered as the optimal treatment for patients with Gram-negative bacterial BSIs except for , which was treated according to the drug sensitivity or multidrug combination.
: 革兰氏阴性菌血流感染（BSI）与高发病率和死亡率相关。本研究在中国北京的一家三级医院检查了革兰氏阴性菌 BSI 的发病率、临床特征、微生物特征、耐药性和死亡率。: 这是一项对革兰氏阴性菌 BSI 患者的回顾性队列研究，在 2010 年 1 月 1 日至 2018 年 12 月 31 日期间在中国人民解放军总医院进行。: 9 年来，3199 名患者共发生 6867 例革兰氏阴性菌 BSI。革兰氏阴性菌 BSI 的总发病率在 9 年内从每 1000 例入院 2.30 至 2.55 例波动。铜绿假单胞菌是主要病原体（34.3%）。产 ESBLs 的 对包括大多数抗生素在内的抗生素的耐药性高于非产 ESBLs 的 ，但对碳青霉烯类药物（0.7% VS 5.1%）的耐药性较低。2010 年至 2018 年期间，革兰氏阴性菌 BSI 的总死亡率从 11.41%降至 9.05%（X = 6.95，P = 0.434）。: 头孢菌素类和碳青霉烯类抗生素被认为是治疗革兰氏阴性菌 BSI 的最佳选择，除 外，根据药敏试验或联合使用多种药物进行治疗。
